BR112022004645A2 - Terapias combinadas com antibióticos - Google Patents

Terapias combinadas com antibióticos

Info

Publication number
BR112022004645A2
BR112022004645A2 BR112022004645A BR112022004645A BR112022004645A2 BR 112022004645 A2 BR112022004645 A2 BR 112022004645A2 BR 112022004645 A BR112022004645 A BR 112022004645A BR 112022004645 A BR112022004645 A BR 112022004645A BR 112022004645 A2 BR112022004645 A2 BR 112022004645A2
Authority
BR
Brazil
Prior art keywords
combination therapies
antibiotics
antibiotic
cefiderocol
baumannii
Prior art date
Application number
BR112022004645A
Other languages
English (en)
Portuguese (pt)
Inventor
Christian Kemmer
E Dale Glenn
Marc Gitzinger
Sergio Lociuro
Vincent Trebosc
Original Assignee
BioVersys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioVersys AG filed Critical BioVersys AG
Publication of BR112022004645A2 publication Critical patent/BR112022004645A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112022004645A 2019-09-12 2020-08-03 Terapias combinadas com antibióticos BR112022004645A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US202062977659P 2020-02-17 2020-02-17
PCT/IB2020/000645 WO2021048610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Publications (1)

Publication Number Publication Date
BR112022004645A2 true BR112022004645A2 (pt) 2022-06-21

Family

ID=72432957

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022004645A BR112022004645A2 (pt) 2019-09-12 2020-08-03 Terapias combinadas com antibióticos
BR112022004672A BR112022004672A2 (pt) 2019-09-12 2020-08-03 Métodos de tratamento com rifabutina, usos e composições

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022004672A BR112022004672A2 (pt) 2019-09-12 2020-08-03 Métodos de tratamento com rifabutina, usos e composições

Country Status (17)

Country Link
US (6) US11351158B2 (cg-RX-API-DMAC7.html)
EP (3) EP4028001B1 (cg-RX-API-DMAC7.html)
JP (4) JP7804570B2 (cg-RX-API-DMAC7.html)
KR (1) KR102991225B1 (cg-RX-API-DMAC7.html)
CN (3) CN115052597B (cg-RX-API-DMAC7.html)
AU (2) AU2020347536B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022004645A2 (cg-RX-API-DMAC7.html)
CA (2) CA3154317A1 (cg-RX-API-DMAC7.html)
ES (1) ES2982067T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240818T1 (cg-RX-API-DMAC7.html)
HU (1) HUE066936T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022003077A (cg-RX-API-DMAC7.html)
PH (1) PH12022550610A1 (cg-RX-API-DMAC7.html)
PL (1) PL4028001T3 (cg-RX-API-DMAC7.html)
RS (1) RS65681B1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400250T1 (cg-RX-API-DMAC7.html)
WO (2) WO2021048610A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
WO2012106364A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
US10953070B2 (en) * 2014-07-25 2021-03-23 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
EP3189154B1 (en) * 2014-09-04 2023-03-22 Labrador Diagnostics LLC Pathogen and antimicrobial resistance testing
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
CN109789125B (zh) * 2016-08-16 2022-10-18 罗切斯特大学 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物
CA3055311A1 (en) * 2017-02-07 2018-08-16 Stc.Unm Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii
US20230364065A1 (en) * 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Also Published As

Publication number Publication date
US20210077471A1 (en) 2021-03-18
PH12022550610A1 (en) 2023-03-13
AU2020344214B2 (en) 2026-01-22
ES2982067T3 (es) 2024-10-14
EP4028000A1 (en) 2022-07-20
WO2021048610A1 (en) 2021-03-18
BR112022004672A2 (pt) 2022-06-07
US11351158B2 (en) 2022-06-07
PL4028001T3 (pl) 2024-07-22
HRP20240818T1 (hr) 2024-10-11
HUE066936T2 (hu) 2024-09-28
JP2025176113A (ja) 2025-12-03
JP2022551228A (ja) 2022-12-08
US12257241B2 (en) 2025-03-25
US11766425B2 (en) 2023-09-26
US20220184048A1 (en) 2022-06-16
MX2022003077A (es) 2022-07-11
RS65681B1 (sr) 2024-07-31
CN115052597A (zh) 2022-09-13
US20240041845A1 (en) 2024-02-08
EP4420673A3 (en) 2024-11-06
SMT202400250T1 (it) 2024-07-09
KR20220103698A (ko) 2022-07-22
US11207305B2 (en) 2021-12-28
CN114980889A (zh) 2022-08-30
AU2020347536A1 (en) 2022-04-14
US20230132691A1 (en) 2023-05-04
JP7804570B2 (ja) 2026-01-22
CN120860031A (zh) 2025-10-31
AU2020344214A1 (en) 2022-04-21
CA3154129A1 (en) 2021-03-18
AU2020347536B2 (en) 2025-09-25
EP4028001B1 (en) 2024-04-10
CA3154317A1 (en) 2021-03-18
US11833139B2 (en) 2023-12-05
WO2021048611A1 (en) 2021-03-18
KR102991225B1 (ko) 2026-07-14
JP7769605B2 (ja) 2025-11-13
US20250281469A1 (en) 2025-09-11
US20210077472A1 (en) 2021-03-18
JP2026016690A (ja) 2026-02-03
CN115052597B (zh) 2025-07-08
EP4028001C0 (en) 2024-04-10
JP2022548252A (ja) 2022-11-17
EP4028001A1 (en) 2022-07-20
EP4420673A2 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
BR112019010342A2 (pt) composições do irna de serpina1 e métodos de uso destas
GT201700246A (es) Métodos y kits para tratar la depresión
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
BR112018003985A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CL2023002946A1 (es) Tratamiento conjunto antineoplásico
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
MX391859B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
CL2017001362A1 (es) Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
BR112018010418A8 (pt) complexo de agente quimioterápico em microbolhas para terapia sonodinâmica
BR112019003172A2 (pt) frações de plasma sanguíneo como tratamento para distúrbios cognitivos associados ao envelhecimento
BR112016019920A8 (pt) dispositivo médico implantável
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
CL2017003152A1 (es) Composiciones de hidroxipropil beta-ciclodextrina y métodos
BR112015024234A2 (pt) composição de liberação sustentada injetável e método para o uso da mesma para tratar inflamação em articulações e dor associada com a mesma
MX2019006950A (es) Metodos para tratar la sinaptopatia coclear.
MX2018003301A (es) Inhibidores de pcna.
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
MX378273B (es) Compuestos activos hacia bromodominios.
EP4378535A3 (en) Antibiotic formulations for lower back pain
GB2543453A (en) Acinetobacter lysins
BR112018001814B8 (pt) Unidade de contêiner médica para planejamento e/ou fabricação de um implante específicos de paciente, anatomicamente adaptados
MX2020004118A (es) Composiciones y metodos para tratar enfermedades de liberibacter y otras enfermedades bacterianas.
MY200797A (en) Substituted xanthine derivatives

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]